IDXX
IDEXX Laboratories, Inc. · Healthcare · Medical - Diagnostics & Research
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 4 | 0 | 293.84K | $152.97M | n/a | −3 |
| Q2 2026 | 166 | 0 | 54.95M | $28.94B | +7 | −8 |
| Q1 2026 | 170 | +1 | 53.67M | $30.16B | +5 | −5 |
| Q4 2025 | 168 | +2 | 58.18M | $39.32B | +3 | n/a |
| Q3 2025 | 21 | +1 | 29.88M | $19.09B | +1 | −1 |
| Q2 2025 | 18 | 0 | 26.38M | $14.14B | +1 | −1 |
| Q1 2025 | 15 | -2 | 9.43M | $3.96B | n/a | −2 |
| Q4 2024 | 17 | -1 | 9.47M | $3.92B | n/a | −1 |
| Q3 2024 | 17 | +1 | 5.70M | $2.88B | +1 | n/a |
| Q2 2024 | 16 | n/a | 5.12M | $2.49B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Assenagon Asset Management S.A. | 256.36K | -30.0% | $133.87M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 2 | Ninety One UK Ltd | 17.90K | -3.8% | $9.35M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 3 | Wealth Enhancement Advisory… | 14.04K | +8.5% | $6.88M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 4 | TD Waterhouse Canada Inc. | 5.55K | -3.0% | $2.87M | 0.0% | ▼ Trim | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Robeco Institutional Asset… | $90.75M | was 0.1% |
| Assetmark, Inc | $24.44M | was 0.0% |
| Parnassus Investments, Llc | $15.47M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1,302 holders, 70.72M shares, $38.50B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 2.20K sh · $1.17M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology